Actively Recruiting

Age: 18Years - 100Years
All Genders
ID05706194

Early Neurological Prognostication of Outcome After Out-of-hospital Cardiac Arrest A STEPCARE Prospective Substudy

Led by Lund University · Updated on 2024-03-21

1000

Participants Needed

4

Research Sites

82 weeks

Total Duration

On this page

Sponsors

L

Lund University

Lead Sponsor

H

Helsingborgs Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating whether the neurological outcome after an out-of-hospital cardiac arrest can be predicted earlier than the currently recommended 72-hour time point. This study focuses on adult patients who suffered a cardiac arrest of presumed cardiac or unknown cause and are unconscious after resuscitation. It explores combining clinical exams, brain injury markers like neurofilament light (NFL), EEG, and head CT scans to predict poor functional outcomes at 24 hours post-arrest without false positives. The study is a prospective observational substudy within the larger STEPCARE trial, conducted by Lund University and involving multiple international centers. The study involves collecting blood samples to measure brain injury markers at 12, 24, 48, and 72 hours after randomization. EEG and CT scans are performed as early as possible after 24 hours in patients still unconscious. Additional neuroimaging and electrophysiological data, including SSEP and MRI, are collected for central blind review. Patients receive intensive care according to STEPCARE trial protocols, which include varying sedation, fever treatment, and blood pressure targets, but decisions about life-sustaining therapy withdrawal follow current guidelines and are not made solely on early exam results. Participants will be assessed with clinical exams, blood tests, EEG, and imaging during their hospital stay, with data stored securely using study IDs. Functional outcomes are evaluated six months after randomization using the modified Rankin Scale, with poor outcomes defined as moderate to severe disability or death. The study aims to determine whether early prognostic tools can predict neurological outcomes accurately and safely, with final biomarker analyses performed after trial completion.

CONDITIONS

Brief Title

Early Neuroprognostication After OHCA

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult cardiac arrest patients with an out-of-hospital cardiac arrest of non-traumatic cause treated at hospitals recruiting patients to the STEPCARE neuroprognostication substudy
  • At least 20 minutes without chest compressions
  • Unconsciousness defined as inability to obey verbal commands or being intubated and sedated due to agitation after sustained return of spontaneous circulation
  • Eligible for intensive care without restrictions
  • Inclusion within 4 hours of return of spontaneous circulation
Not Eligible

You will not qualify if you...

  • On ECMO prior to randomisation
  • Pregnancy
  • Suspected or confirmed intracranial hemorrhage
  • Previously randomised in the STEPCARE trial
  • Patients with limitations in level-of-care due to conditions like generalized malignancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 to 2 visits during initial hospital care

Diagnostic Evaluation

Duration - Up to 72 hours post-randomisation

Participants have biomarker blood samples collected at multiple timepoints and undergo EEG and CT scans to assess neurological status after cardiac arrest.

Blood samples collected at 12, 24, 48, and 72 hours; EEG and CT performed as early as possible after 24 hours in unconscious patients

Long-term Monitoring

Duration - Six months post-randomisation

Participants' functional outcomes are assessed at six months after the cardiac arrest to evaluate recovery and disability.

1 face-to-face follow-up visit

Trial Site Locations

Total: 4 locations

1

Helsinki Hospital

Helsinki, Finland

Actively Recruiting

2

Charité University Hospital

Berlin, Germany

Actively Recruiting

3

Helsingborgs Hospital

Helsingborg, Sweden

Actively Recruiting

4

Skane University Hospital

Lund, Sweden

Actively Recruiting

Loading map...

Research Team

M

Marion Moseby-Knappe, MD, PhD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

The Performance of Spectral CT in Evaluating Treatment Respo...

HCC - Hepatocellular Carcinoma

Actively Recruiting

1 location

Adebrelimab with or Without Induction Chemotherapy Followed ...

Esophageal Squamous Cell Carcinoma

Actively Recruiting

1 location

Artificial Intelligence-assisted CT for Risk Stratification ...

Coronary Artery Disease (CAD)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here